SMS Pharmaceuticals Ltd
NSE: SMSPHARMA BSE: 532815
₹385.20
(-1.08%)
Tue, 03 Mar 2026, 11:22 pm
Market Cap35.98B
PE Ratio38.72
Dividend0.10
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1987
- Incorporated as S.M.S. Pharmaceuticals Pvt. Ltd. for the manufacture of Bulk Drugs by Mr. K G Suggula
1988
- Issued 49,960 equity shares at the price of Rs. 10 per share
1989
- Issued 50,000 equity shares at the price of Rs. 10 per share
1990
- Acquired by present promoters Mr. Ramesh Babu Potluri & Mr. T V V S N Murthy
- Issued 50,000 equity shares at the price of Rs. 10 per share
1991
- Commercial production of Ranitidine HCL with 3 MTPA at Unit I
1992
- Ranitidine capacity increased to 180 MTPA
- Issues 150,000 equity shares at the price of Rs. 10 per share
1994
- Issued Bonus Shares in the ratio of 8:3
- Issued 150,000 equity shares at the price of Rs. 10 per share and 350,000 equity shares at the price of Rs. 60 per share
- Setup of in-house R&D laboratory in Unit I
- Converted to Public Limited Company from private limited and the name was changed to S.M.S. Pharmaceuticals Limited.
1995
- Doubled Ranitidine capacity to 360 MTPA
- Issued 450,000 equity shares at the price of Rs. 120 per share
1997
- Increased Ranitidine capacity to 720 MTPA
1998
- Awarded the prestigious Pandit Jawaharlal Nehru Silver Rolling Trophy for its excellence as Best Industrial Productivity effort in the State
1999
- Additional APIs Naproxen, Ciprofloxacin at Unit I
2000
- Ranitidine capacity including intermediates increased to 1,440 MTPA
- Acquired plant of high value APIs at Bachupally (Unit II)
2001
- Commercial production of Sumatriptan Succinate at Unit II
- ISO 9001:2000 certification obtained for Unit I
- Recognized as export house by Ministry of Commerce
2002
- Setup of in-house R&D laboratory in Unit II
- US DMF filed for Sumatriptan Succinate
2003
- ISO 9001:2000 certification obtained for Unit II
- Supply Agreement with Ranbaxy under Para IV of ANDA for Sumatriptan Succinate
- 4 process patents and 1 product patent filed under the Patent Co-operation Treaty
- 1 Process Patent filed for Sumatriptan Succinate under European Patents.
- Set up of Nutraceutical plants in Unit III
2004
- USFDA approval obtained for Unit II
- Commenced commercial production of Ramipril and Quinapril at Unit II
- Established exclusive basic research facility at Sanath Nagar, Hyderabad
- US DMF for Ranitidine HCL and CoS filed for Sumatriptan Succinate and Ramipril
- Agreement entered into with IICT, Hyderabad for development of process know-how for Diltiazem HCL and Taxol C-13
- Agreement entered into with IIT, Guwahati for development of process know-how for metal acetylacetonates
- Entered into a Memorandum of Understanding with Sochinaz SA for exclusive development and supply of Trandolapril for global marketing by Sochinaz SA.
- Setup of pilot plant facility for APIs at Gagilapur, Hyderabad (Unit IV)
- 1 process patents filed under the Patent Co-operation Treaty and 2 process patents filed with Indian Patents Office
- Issued Bonus Shares in the ratio of 1:1
2005
- 8 process patents filed with Indian Patents Office
- Commenced commercial production of Almotriptan in Unit II
- US DMF filed for Ranitidine USP, Almotriptan and Ramipril.
- Commencement of development of Trandolapril product under Contact Research for a European Company Sochinaz S/A.
2006
- Published European Patent for Sumatriptan Succinate
- Issued 2,923,000 equity shares to the shareholders of Sreenivasa Pharma Private Limited in exchange of shares of Sreenivasa Pharma Pvt. Limited.
- Completion of contract research assignment of Trandolapril exclusively executed for Sochinaz SA
- CoS for Ranitidine HCL obtained from EDQM.
2007
- Issued 400,000 equity shares at the price of Rs. 350 per share to Gulf Pharmaceutical Industries.
- CoS for Ranitidine HCL obtained from EDQM.
- Completion of contract research assignment of Trandolapril exclusively executed for Sochinaz SA
- Published European Patent for Sumatriptan Succinate
2010
- SMS Pharmaceuticals Ltd has appointed Mr. N. Rajendra Prasad as Chief Financial Officer of the Company.
2011
- Mr. K. Umamaheswaram is appointed as Nominee Director of the Company.
- The Board has recommended dividend of Rs. 1.50 per equity share of Rs. 10/- each on the paid up share capital of the company.
2012
- SMS Pharmaceuticals appointed Mr. Utpal Gokhale as a new nominee Director.
2013
- SMS Pharmaceuticals has recommended dividend of Rs. 2.00 per equity share of Rs. 10/- each.
2014
- SMS Pharmaceuticals has recommended dividend of Rs. 2.00 per equity share of Rs. 10/- each.
2015
- SMS Pharmaceuticals Limited has won India Pharma bulk drug company of the year award.
- SMS Pharmaceuticals splits its face value from Rs. 10 to Rs. 1
2017
- SMS Pharmaceuticals hikes stake in VKT Pharma.
2018
- SMS Pharmaceuticals gets EIR for Bachupally facility.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800